On August 1, 2017, Boston Heart Diagnostics Corporation (“BHDC”) sued Defendant Genelex Corporation for infringement of BHDC’s U.S. Patent No. 8,455,194, entitled “Diagnostic Methods.”
BHDC accuses the Genelex SLCO1B1 Test as infringing the ’194 patent directly and/or through inducement. The accused test works to identify patients who are at a higher risk of developing statin-induced myopathy due to a SLCO1B1 gene variation.
The case is captioned CTD-3-17-cv-01296, in the United States District Court for the District of Massachusetts.
By: Joyce L. Nadipuram